caa a22 4500 445824573 CHVBK 20180317145255.0 cr unu---uuuuu 170323e20111001xx s 000 0 eng 10.1007/s00246-011-0020-y doi (NATIONALLICENCE)springer-10.1007/s00246-011-0020-y Early NT-proBNP Is Able to Predict Spontaneous Closure of Patent Ductus Arteriosus in Preterm Neonates, But Not the Need of Its Treatment [Elektronische Daten] [D. Martinovici, S. Vanden Eijnden, P. Unger, B. Najem, B. Gulbis, Y. Maréchal] The objective of this study was to establish the potential utility of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the management of patent ductus arteriosus (PDA). This was a monocentric prospective blind study that was conducted in a referral neonatal intensive care unit. The patients were very low-birth-weight/gestational-age neonates. Babies with cardiac congenital anomaly other than PDA, life-threatening congenital malformation, severe asphyxia at birth, persistent pulmonary hypertension, and death within the first week of life were excluded. Plasma NT-proBNP concentrations were determined on days 2, 4, and 7 of life. Echocardiography was performed on days 4 and 7. Results were blinded to clinicians. Only echographic results were available upon request. Thirty-one infants were included. NT-proBNP levels were significantly correlated to ductal size and to left atrial-to-aortic diameter ratio. The median NT-proBNP on both days 2 and 4 was significantly higher in neonates with later treated or persistent PDA. A level above 10.000pg/mL at 48h of age yielded a 100% positive and a 87% negative predictive value to exclude spontaneous ductal closure. However, no NT-proBNP threshold could predict which PDA would be judged necessary to treat. It was concluded that early low NT-proBNP values can be used as a reliable independent marker to predict spontaneous ductal closure in preterm neonates. Yet, high NT-proBNP levels should not be used to guide the decision to treat PDA, the risk being of treating many bystanding PDAs. Springer Science+Business Media, LLC, 2011 NT-proBNP nationallicence PDA nationallicence Preterm nationallicence Martinovici D. Neonatal Intensive Care Unit, ULB-Erasme Hospital, 808 Route de Lennik, 1070, Brussels, Belgium aut Vanden Eijnden S. Neonatal Intensive Care Unit, ULB-Erasme Hospital, 808 Route de Lennik, 1070, Brussels, Belgium aut Unger P. Department of Cardiology, ULB-Erasme Hospital, Brussels, Belgium aut Najem B. Department of Cardiology, ULB-Erasme Hospital, Brussels, Belgium aut Gulbis B. Department of Clinical Chemistry, ULB-Erasme Hospital, Brussels, Belgium aut Maréchal Y. Neonatal Intensive Care Unit, ULB-Erasme Hospital, 808 Route de Lennik, 1070, Brussels, Belgium aut Pediatric Cardiology Springer-Verlag 32/7(2011-10-01), 953-957 0172-0643 32:7<953 2011 32 246 https://doi.org/10.1007/s00246-011-0020-y text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00246-011-0020-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Martinovici D. Neonatal Intensive Care Unit, ULB-Erasme Hospital, 808 Route de Lennik, 1070, Brussels, Belgium aut NATIONALLICENCE 700 1- Vanden Eijnden S. Neonatal Intensive Care Unit, ULB-Erasme Hospital, 808 Route de Lennik, 1070, Brussels, Belgium aut NATIONALLICENCE 700 1- Unger P. Department of Cardiology, ULB-Erasme Hospital, Brussels, Belgium aut NATIONALLICENCE 700 1- Najem B. Department of Cardiology, ULB-Erasme Hospital, Brussels, Belgium aut NATIONALLICENCE 700 1- Gulbis B. Department of Clinical Chemistry, ULB-Erasme Hospital, Brussels, Belgium aut NATIONALLICENCE 700 1- Maréchal Y. Neonatal Intensive Care Unit, ULB-Erasme Hospital, 808 Route de Lennik, 1070, Brussels, Belgium aut NATIONALLICENCE 773 0- Pediatric Cardiology Springer-Verlag 32/7(2011-10-01), 953-957 0172-0643 32:7<953 2011 32 246 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer